CG Oncology, Inc. $CGON Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH increased its stake in CG Oncology by 623.8%, buying 32,607 shares to hold 37,834 shares valued at approximately $1.57 million.
• CG Oncology shares opened at $66.27 (52‑week range $21.00–$73.56) with a market cap of $5.83 billion; the company reported Q4 EPS of $(0.51) versus $(0.61) expected and revenue of $2.32 million.
• Analysts maintain a consensus rating of “Moderate Buy” with an average target of $79.55 after several target increases, while insider Director James Mulay sold 15,600 shares (~$1.14M) and insiders own 7.4% of the stock.

Universal Beteiligungs und Servicegesellschaft mbH lifted its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 623.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,834 shares of the company's stock after purchasing an additional 32,607 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH's holdings in CG Oncology were worth $1,571,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Whittier Trust Co. of Nevada Inc. acquired a new position in shares of CG Oncology in the 4th quarter valued at $27,000. Strengthening Families & Communities LLC acquired a new position in shares of CG Oncology in the 3rd quarter valued at $40,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of CG Oncology by 33.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company's stock valued at $163,000 after purchasing an additional 972 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of CG Oncology by 159.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company's stock valued at $182,000 after purchasing an additional 4,288 shares during the period. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in shares of CG Oncology in the 3rd quarter valued at $208,000. 26.56% of the stock is currently owned by institutional investors and hedge funds.

CG Oncology Stock Down 0.7%

CG Oncology stock opened at $66.27 on Friday. CG Oncology, Inc. has a 52-week low of $21.00 and a 52-week high of $73.56. The firm has a market capitalization of $5.83 billion, a price-to-earnings ratio of -32.01 and a beta of 0.42. The company has a fifty day simple moving average of $65.06 and a 200-day simple moving average of $52.26.

CG Oncology (NASDAQ:CGON - Get Free Report) last released its earnings results on Friday, February 27th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.61) by $0.10. The business had revenue of $2.32 million for the quarter. On average, research analysts anticipate that CG Oncology, Inc. will post -2.56 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on CGON. Truist Financial boosted their price target on shares of CG Oncology from $66.00 to $75.00 and gave the stock a "buy" rating in a report on Tuesday, February 10th. Morgan Stanley set a $93.00 price target on shares of CG Oncology in a report on Friday, January 9th. Piper Sandler boosted their price target on shares of CG Oncology from $55.00 to $70.00 and gave the stock an "overweight" rating in a report on Friday, January 16th. The Goldman Sachs Group reissued a "buy" rating and issued a $82.00 price target on shares of CG Oncology in a report on Monday, January 12th. Finally, Wall Street Zen lowered shares of CG Oncology from a "hold" rating to a "sell" rating in a report on Saturday, April 25th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $79.55.

Insider Buying and Selling at CG Oncology

In other news, Director James Mulay sold 15,600 shares of the business's stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the transaction, the director owned 15,600 shares of the company's stock, valued at approximately $1,138,956. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 7.40% of the company's stock.

About CG Oncology

CG Oncology, Inc NASDAQ: CGON is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.